About
Dr. Jessica Duncan serves as Chief Medical Officer at Ivím Health and holds dual board certifications as a Diplomate of the American Board of Obesity Medicine and a Diplomate of the American Board of Anesthesiology. She has focused her clinical career on obesity medicine, GLP-1 therapy, and metabolic health. Her research has directly shaped how Ivím Health delivers care at scale.
Dr. Duncan led two peer-reviewed retrospective studies published in Obesity Pillars, examining GLP-1 outcomes in more than 2,300 patients. Her work on semaglutide and tirzepatide outcomes has drawn national attention. She has contributed clinical commentary to Medscape on GLP-1 prescribing practices and appeared on SiriusXM Patriot Channel to discuss the 2025-2030 Dietary Guidelines. She is deeply engaged in weight regain prevention and the long-term clinical management of obesity and metabolic disease.
Certifications
Conditions Treated
Who is Dr. Duncan right for?
Dr. Duncan is an excellent fit for adults dealing with obesity, overweight, or metabolic disease, including type 2 diabetes. Patients who have experienced weight regain after prior treatment will benefit from her specific focus on long-term management strategies. Women navigating perimenopause or menopause-related weight changes and metabolic shifts will find her dual expertise in hormone optimization and obesity medicine particularly relevant. Patients who want evidence-based, research-informed care from a physician who has published on real-world GLP-1 outcomes will feel well supported under her clinical direction.
Similar Doctors Nearby
Frequently Asked Questions
Yes. Dr. Jessica Duncan holds board certification as a Diplomate of the American Board of Obesity Medicine. She also holds board certification from the American Board of Anesthesiology. These dual certifications reflect both her clinical depth in obesity care and her broader medical training.
Dr. Duncan focuses on obesity, overweight, metabolic disease, type 2 diabetes, and weight regain. She has a particular clinical interest in GLP-1 therapy and the long-term management of metabolic health. She also oversees Ivím Health's Women's Hormone Optimization program for patients experiencing perimenopause and menopause symptoms.
Yes. Dr. Duncan led two peer-reviewed retrospective observational studies published in Obesity Pillars. The studies examined GLP-1 outcomes across more than 2,300 Ivím Health patients on semaglutide and tirzepatide. She also contributed a clinical perspective on GLP-1 weight regain to KevinMD and provided commentary to Medscape on GLP-1 prescribing practices.
8% at 68 weeks. 54% average weight loss. Both studies appeared in the peer-reviewed journal Obesity Pillars.
Yes. Weight regain prevention is a core clinical interest for Dr. Duncan. She published a clinical perspective on GLP-1 weight regain on KevinMD and actively incorporates long-term maintenance strategies into treatment planning at Ivím Health.
Dr. Duncan emphasizes individualized dosing and continuous clinical monitoring. Her research supports the view that frequent provider check-ins and dosage adjustments based on individual progress drive better outcomes. She applies that same philosophy to her oversight of Ivím Health's GLP-1 programs.
Yes. Dr. Duncan appeared on SiriusXM Patriot Channel 125 on The David Webb Show to discuss the 2025-2030 Dietary Guidelines. She has also contributed clinical commentary to Medscape on GLP-1 prescribing. Ivím Health's research and clinical outcomes have received coverage in The New York Times, TIME, Forbes, and other national outlets.
Yes. Dr. Duncan oversees Ivím Health's Women's Hormone Optimization program. That program addresses perimenopausal and menopausal symptoms including fatigue, weight gain, low libido, mood swings, sleep disturbances, hot flashes, night sweats, and brain fog. Her combined focus on metabolic health and hormone optimization makes her well suited to treat the interconnected nature of these conditions.
Doctor profile last updated April 17, 2026